Barbiturate treatment vs placebo or no treatment: Major neurodevelopmental disability at childhood
It is very uncertain whether barbiturate treatment changes major neurodevelopmental disability compared with placebo or no treatment (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Barbiturate treatment vs placebo or no treatment Major neurodevelopmental disability · infants with perinatal asphyxia It is very uncertain whether barbiturate treatment changes major neurodevelopmental disability compared with placebo or no treatment (very low certainty). Prophylactic barbiturate use for the prevention of morbidity and mortality following perinatal asphyxia (2016) · Cochrane Headline outcomes only | RR 0.24 [0.06, 0.92] | 1 study · 31 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Prophylactic barbiturate use for the prevention of morbidity and mortality following perinatal asphyxia 2016 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.